On March 6, biotechnology developer Amgen filed a reply brief with the U.S. Supreme Court in its appeal of the invalidation of its patent claims covering antibodies effective at blocking low-density lipoprotein (LDL) cholesterol receptors. The brief responds to arguments raised both by rival pharmaceutical firm Sanofi and the U.S. federal government in Amgen’s appeal of the invalidation of its patent claims as a matter of law under 35 U.S.C. § 112, which the district court entered on judgment as a matter of law (JMOL) after a jury verdict upheld the validity of Amgen’s patent claims.
Recent Posts
- Revised Fair Use Ruling Finds No Transformative Use in Developing AI Search Tool
- Patently Strategic Podcast: Dealing with Rejection
- IPWatchdog Unleashed: Patents and the Future of the USPTO in Trump’s Second Term
- No Infringement Intended – The World Wrestling Federation’s Biggest Fight: A Look at Trademark Law and Global Brand Recognition
- Other Barks & Bites for Friday, February 7: CAFC Rejects Untimely Expert Testimony and Reassigns Case; CJEU Clarifies Online Marketplace Responsibilities Under GDPR; and IPWATCHPUPPIES ARE ON THE WAY!